Decreased in vitro osteoblast proliferation and low turnover bone disease in nonuremic proteinuric patients

Kidney International

Volumn 71, Issue 6, 2007, Pages 562-568

  Dias, C B ^a   Dos Reis, L M ^a   Caparbo, V F ^a   Graciolli, F G ^a   Moyses R M A ^a   Barros, R T ^a   Jorgetti, V ^a   Woronik, V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bone histomorphometry; Glomerulopathy; Osteoblasts; Proteinuria; Vitamin D

Indexed keywords

CALCIFEDIOL;

ADULT; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE MINERALIZATION; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GLOMERULOPATHY; HISTOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MORPHOMETRICS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOID; OSTEOLYSIS; PRIORITY JOURNAL; PROTEINURIA; TRABECULAR BONE; UREMIA; VITAMIN BLOOD LEVEL;

ADULT; BIOPSY; BONE AND BONES; BONE DISEASES; BONE RESORPTION; CALCIFEDIOL; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; OSTEOBLASTS; OSTEOGENESIS; PROTEINURIA;

EID: 33947104192     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002084     Document Type: Article

References (43)

1. 3: implications in cell growth and differentiation. Endrocr Rev 2002; 23: 763-786.
2. 3 levels and bone mass in 24-hydroxylase transgenic rats. FASEB J 2003; 17: 737-739.
3. 3. Artif Cells Blood Substit Immobil Biotechnol 2002; 30: 219-227.
4. Khamiseh G, Vaziri ND, Oveisi F et al. Vitamin D absorption, plasma concentration and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Soc Experim Biol Med 1991; 196: 210-213.
5. Lambert PW, Deoreo PB, Fu IY et al. Urinary and plasma vitamin D3 metabolites in the nephrotic syndrome. Metab Bone Dis Relat Res 1982; 4: 7-15.
6. Schmidt-Gayk H, Grawunder C, Tshope W et al. 25-hydroxyvitamin D in nephrotic syndrome. Lancet 1977; 2: 105-108.
7. Goldstein DA, Haldiman B, Sherman D et al. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metabol 1981; 52: 116-120.
8. Goldstein DA, Oda Y, Korokawa K et al. Blood levels of 25-hydroxyvitamin D in nephrotic syndrome. Studies in 26 patients. Ann Intern Med 1997; 87: 664-667.
9. Lim P, Jacob E, Tock EPC et al. Calcium and phosphorus metabolism in nephrotic syndrome. Q J Med 1997; 183: 327-338.
10. Korkor A, Schwartz J, Bergfeld M et al. Absence of metabolic bone disease in adult patients with the nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1983; 56: 496-500.
11. Malluche HH, Goldstein DA, Massry SG. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 1979; 63: 494-500.
12. Mittal SK, Dash SC, Tiwari SC et al. Bone histology in patients with nephrotic syndrome and normal renal function. Kidney Int 1999; 55: 1912-1919.
13. Tessitore N, Bonucci E, D'Angelo A et al. Bone histology and calcium metabolism in patients with nephrotic syndrome and normal or reduced renal function. Nephron 1984; 37: 153-159.
14. Freundlich M, Bourgoignie JJ, Zilleruelo G et al. Calcium and vitamin D metabolism in children with nephrotic syndrome. J Pediatr 1986; 108: 383-387.
15. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-311.
16. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333: 166-174.
17. Saxena S, Mittal A, Andal A. Pattern of interleukins in minimal change nephrotic syndrome of childhood. Nephron 1993; 65: 56-61.
18. Neuhaus TJ, Wadhwa M, Callard R et al. Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol 1995; 100: 475-479.
19. Bustos C, Gonzalez E, Muley R et al. Increase of tumor necrosis factor alpha synthesis and gene expression in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur J Clin Invest 1994; 24: 799-805.
20. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-253.
21. Freundlich M, Alonzo E, Bellorin-Font E et al. Increased osteoblastic activity and expression of receptor activator of NF-κB ligand in nonuremic nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2198-2204.
22. Martini LA, Cuppari L, Cunha MA et al. Potassium and sodium intake and excretion in calcium stone forming patients. J Renal Nutr 1998; 8: 127-131.
23. Lettgen B, Jeken C, Reiners C. Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatr Nephrol 1994; 8: 667-670.
24. Hegarty J, Mughal LM, Adans J et al. Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome. Kidney Int 2005; 68: 2304-2309.
25. Chan YL, Manson RS, Parmentier M et al. Vitamin D metabolism in nephrotic rats. Kidney Int 1983; 24: 336-341.
26. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80(Suppl 6): S1678-S1688.
27. Horst RL, Reinhardt TA. Vitamin D Metabolism. In: Felman D, Glorieux FH, Pike JW (eds). Vitamin D. San Diego: Academic Press, 1997 pp. 13-31.
28. Hewinson M, Zehnder D, Bland R et al. 1α-hydroxylase and the action of vitamin D. J Molec Endocrinol 2000; 25: 141-148.
29. Nordin BEG, Need AG. The relation between serum calcidiol and calcitriol. Bone 2005; 2: 7-16.
30. Holick MF. Vitamin D: importance in the prevention of cancres, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004; 79: 362-371.
31. Thomas MK, Lloyd-Jones DM, Thadhani RI et al. Hypovitaminosis D in medical inpatients. New Engl J Med 1998; 338: 777-783.
32. Gómez-Alonso C, Naves-Díaz ML, Fernández- Martín JL et al. Vitamin 25-hydroxyvitamin D cut-off levels. Kidney Int 2003; 63(Suppl 85): S44-S48.
33. Kurokouchi K, Kambe F, Yasukawa K et al. TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells. J Bone Miner Res 1998; 13: 1290-1299.
34. Marie PJ, Lomri A, Vernejoul MC et al. Relationships between histomorphometric features of bone formation and bone cell characteristics in vitro in renal osteodystrophy. J Clin Endocinol Metabol 1989; 69: 1166-1173.
35. Sánchez MC, Bajo MA, Selgas R et al. Cultures of human osteoblastic cells from dialysis patients: influence of bone turnover rate on in vitro secretion of interleukin-6 and osteoblastic cell markers. Am J Kidney Dis 2001; 37: 30-37.
36. Levery A, Bosch J, Breyer Lewis J et al. A more accurate method to estimate glomerular filtration rate from serum creatinine. Ann Intern Med 1999; 139: 461-470.
37. Hollis BW. Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure. Clin Chem 1986; 32: 2060-2063.
38. Malluche HH, Faugere MC (eds). Methodology of mineralized bone histology, in ATLAS of mineralized bone histology. Karger: Basel, Switzerland, 1986, pp 17-24.
39. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 1987; 2: 595-609.
40. Dos Reis LM, Batalha JFR, Cardoso LA et al. Age related histomorphometric changes in bone in normal Brazilian men and women. Bone 1998; 23(Suppl 5): S476.
41. Melsen F, Mosekilde L. Tetracycline double-labeling of trabecular bone in 41 normal adults. Calcif Tissue Res 1978; 26: 99-102.
42. Wergedal JE, Baylink DJ. Characterization of cells isolated and cultured from human bone. Proc Soc Exp Biol Med 1984; 176: 60-69.
43. Robey PG, Termine JD. Human bone cell in vitro. Calcif Tissue Int 1985; 37: 453-460.